Evidence map›Paper›PMID 28813479›Full record

ArticlePloS one2017

Metabolomic profiling of amines in sepsis predicts changes in NOS canonical pathways.

Abel Tesfai, Niall MacCallum, Nicholas S Kirkby, Hime Gashaw, Nicola Gray, Elizabeth Want, Gregory J Quinlan, Sharon Mumby, James M Leiper, Mark Paul-Clark and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Abel TesfaiCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Niall MacCallumCritical Care, University College London Hospital, London, United Kingdom; formerly critical care, National Heart and Lung Institute, Imperial College London, United Kingdom.
Nicholas S KirkbyCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Hime GashawCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Nicola GrayDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.
Elizabeth WantDepartment of Surgery and Cancer, Imperial College London, London, United Kingdom.
Gregory J QuinlanCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Sharon MumbyRespiratory, Airway Disease, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
James M LeiperMRC Clinical Sciences, Imperial College London, Hammersmith Hospital, London, United Kingdom.
Mark Paul-ClarkCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Blerina Ahmetaj-ShalaCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.ORCID http://orcid.org/0000-0003-4488-7689
Jane A MitchellCardiothoracic Pharmacology, Vascular Biology, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Imperial College London · GBHammersmith Hospital · GBUniversity College Hospital · GB

Funding

British Heart Foundation FS/16/1/31699British Heart Foundation PG/14/27/30679British Heart Foundation PG/16/83/32467Medical Research Council MC_U120097118Wellcome Trust
6 · The paper itself

Abstract

rationaleNitric oxide synthase (NOS) is a biomarker/target in sepsis. NOS activity is driven by amino acids, which cycle to regulate the substrate L-arginine in parallel with cycles which regulate the endogenous inhibitors ADMA and L-NMMA. The relationship between amines and the consequence of plasma changes on iNOS activity in early sepsis is not known.

objectiveOur objective was to apply a metabolomics approach to determine the influence of sepsis on a full array of amines and what consequence these changes may have on predicted iNOS activity. METHODS AND MEASUREMENTS: 34 amino acids were measured using ultra purification mass spectrometry in the plasma of septic patients (n = 38) taken at the time of diagnosis and 24-72 hours post diagnosis and of healthy volunteers (n = 21). L-arginine and methylarginines were measured using liquid-chromatography mass spectrometry and ELISA. A top down approach was also taken to examine the most changed metabolic pathways by Ingenuity Pathway Analysis. The iNOS supporting capacity of plasma was determined using a mouse macrophage cell-based bioassay. MAIN

resultsOf all the amines measured 22, including L-arginine and ADMA, displayed significant differences in samples from patients with sepsis. The functional consequence of increased ADMA and decreased L-arginine in context of all cumulative metabolic changes in plasma resulted in reduced iNOS supporting activity associated with sepsis.

conclusionsIn early sepsis profound changes in amine levels were defined by dominant changes in the iNOS canonical pathway resulting in functionally meaningful changes in the ability of plasma to regulate iNOS activity ex vivo.

Indexed as

MetabolomicsAdultAgedAminesAnimalsArginineCell LineChromatography, LiquidEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMass SpectrometryMiceMiddle AgedNitric Oxide SynthaseAminesArginineNitric Oxide SynthaseNitric Oxide Synthase Type IIomega-N-Methylarginine

Identifiers

PMID28813479
PMCPMC5557592
OpenAlexW2750346951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.